Journal article
Perfusion mammalian cell culture for recombinant protein manufacturing - A critical review.
-
Bielser JM
Biotech Process Sciences, Merck KGaA, Corsier-sur-Vevey, Switzerland; Institute of Chemical and Bioengineering, ETH Zürich, Zürich, Switzerland. Electronic address: jean-marc.bielser@merckgroup.com.
-
Wolf M
Institute of Chemical and Bioengineering, ETH Zürich, Zürich, Switzerland.
-
Souquet J
Biotech Process Sciences, Merck KGaA, Corsier-sur-Vevey, Switzerland.
-
Broly H
Biotech Process Sciences, Merck KGaA, Corsier-sur-Vevey, Switzerland.
-
Morbidelli M
Institute of Chemical and Bioengineering, ETH Zürich, Zürich, Switzerland. Electronic address: massimo.morbidelli@chem.ethz.ch.
Show more…
Published in:
- Biotechnology advances. - 2018
English
The manufacturing of recombinant protein is traditionally divided in two main steps: upstream (cell culture and synthesis of the target protein) and downstream (purification and formulation of the protein into a drug substance or drug product). Today, cost pressure, market uncertainty and market growth, challenge the existing manufacturing technologies. Leaders in the field are active in designing the process of the future and continuous manufacturing is recurrently mentioned as a potential solution to address some of the current limitations. This review focuses on the application of continuous processing to the first step of the manufacturing process. Enabling technologies and operation modes are described in the first part. In the second part, recent advances in the field that have the potential to support its successful future development are critically discussed.
-
Language
-
-
Open access status
-
hybrid
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/global/documents/37311
Statistics
Document views: 39
File downloads: